Purpose: The objectives of this study are to (1) quantify intrafraction motion (IFM) during lung volumetric-modulated arc therapy (VMAT) and (2) evaluate the impact of mid-treatment patient repositioning after cone beam computed tomography (CBCT) acquisition upon target coverage.
delineation was performed. A 5 mm margin was added in all directions to obtain the final planning target volume (PTV). Treatment sessions were performed in supine position with a customized dual vacuum immobilization device (BodyFIX, Elekta, Stockholm, Sweden). All patients underwent pre and mid-treatment CBCTs to ensure proper repositioning. Following each CBCT, a two-step rigid registration was performed by an experienced radiation oncologist according to the planning CT, taking into account organs at risk (OARs). Bone shift was first assessed with a registration of the vertebrae adjacent to the lesion. Then, tumor shift was isolated with a soft tissue registration by aligning targets. IFM, combining bone and tumor shifts, was defined as the target displacement from pre to mid-treatment CBCT acquisition and was quantified in terms of anterior-posterior (AP), cranio-caudal (CC) and medio-lateral (ML) amplitudes as well as three-dimensional (3D) vector.
For patients with IFM ≥ 5 mm, a post hoc dose calculation analysis was performed to assess target coverage impacts of mid-treatment CBCT-guided repositioning. 
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